Skip to contentA
Atara Biotherapeutics, Inc.
A
ATRAAtara Biotherapeutics, Inc. Released Aug 7, 2017, after the close
10-Q filed Aug 7, 2017, 38 days after period end · 0001564590-17-016028
Q2 2017 · 10-Q
Revenue—
Net Income-$27.43M-$27.43MN/M vs Q2 2016N/M vs Q1 2017 EPS, diluted
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR
—
Operating Income-$27,909,000N/M Operating Cash Flowderived-$20,301,000N/M Free Cash Flowderived-$23,436,000N/M ended Jun 30, 2017 · filed Aug 7, 2017 · 38 d after period end
4.8% from the close of Aug 7, 2017 to the close of Aug 8, 2017, the first after the release.
after the close$15.55$14.80 Jun 29Aug 7Sep 14